Results 51 to 60 of about 41,162 (299)

Sequential Blockade with Loop Diuretics and Acetazolamide: A Novel Strategy in Acute Heart Failure

Journal of the Indian Academy of Geriatrics
Acute decompensated heart failure (HF) is the most common form of acute HF (AHF) and presents with systemic congestion due to left ventricular dysfunction with sodium and water retention.
Nitin R. Gaikwad, Madhusudan Prasad Singh, Alok Singh   +2 more
doaj   +1 more source

Nitrates for the Management of Acute Heart Failure Syndromes, A Systematic Review [PDF]

, 2016
© The Author(s) 2016Intravenous nitrates are widely used in the management of acute heart failure syndrome (AHFS) yet with lack of robust evidence to support their use.
Farag, Mohamed, Gorog, Diana A, Shoaib, Ahmad   +2 more
core   +2 more sources

Cryo-EM structure of the potassium-chloride cotransporter KCC4 in lipid nanodiscs. [PDF]

, 2020
Cation-chloride-cotransporters (CCCs) catalyze transport of Cl- with K+ and/or Na+across cellular membranes. CCCs play roles in cellular volume regulation, neural development and function, audition, regulation of blood pressure, and renal function.
Brohawn, Stephen Graf, Kern, David M, Reid, Michelle S   +2 more
core   +2 more sources

Cardiovascular and Renal Outcomes with Ertugliflozin by Baseline Use of Renin-Angiotensin-Aldosterone System Inhibitors or Diuretics, Including Mineralocorticoid Receptor Antagonist: Analyses from the VERTIS CV Trial

Kidney Diseases
Introduction: VERTIS CV was a placebo-controlled cardiovascular (CV) outcome trial evaluating the sodium-glucose cotransporter 2 inhibitor ertugliflozin in patients with type 2 diabetes and established atherosclerotic CV disease.
David Z.I. Cherney, Robert Frederich, Richard E. Pratley, Francesco Cosentino, Samuel Dagogo-Jack, Annpey Pong, Ira Gantz, Nilo B. Cater, James P. Mancuso, Urszula Masiukiewicz, Christopher P. Cannon   +10 more
doaj   +1 more source

Return to the workforce following first hospitalization for heart failure: a Danish nationwide cohort study [PDF]

, 2016
Background: Return to work is important financially, as a marker of functional status and for self-esteem in patients developing chronic illness. We examined return to work after first heart failure (HF) hospitalization.
Fosbøl, Emil L., Gerds, Thomas A., Gislason, Gunnar H., Jhund, Pardeep S., Kragholm, Kristian, Kristensen, Søren L., Køber, Lars, Lamberts, Morten, McMurray, John J.V., Mogensen, Ulrik M., Petrie, Mark C., Rørth, Rasmus, Torp-Pedersen, Christian, Wong, Chih   +13 more
core   +2 more sources

Pharmacogenetics of loop diuretics

Clinical Pharmacology & Therapeutics, 2004
Objective Genetic variability in pharmacokinetics and pharmacodynamics of diuretics is incompletely studied. We compared the extent of variability in different loop diuretics and determined to what extent this is influenced by polymorphisms in candidate genes. Methods Single oral doses of bumetanide 2 mg, furosemide 80 mg and torasemide 10
Vormfelde, Stefan Viktor, Zirk, A., Westermann, J., Torn, M., Tuchen, F., Toliat, Mohammad Reza, Brockmoeller, Juergen   +6 more
openaire   +2 more sources

Rationale and study design of intravenous loop diuretic administration in acute heart failure. DIUR-AHF [PDF]

, 2017
Aims: Although loop diuretics are the most commonly used drugs in acute heart failure (AHF) treatment, their short-term and long-term effects are relatively unknown.
Di Somma, Salvatore, Nuti, Ranuccio, Palazzuoli, Alberto, Ruocco, Gaetano, Valle, Roberto, Vescovo, Giorgio   +5 more
core   +1 more source

Diuretics in chronic kidney disease

Архивъ внутренней медицины, 2020
The issues of diuretic therapy in patients with chronic kidney disease, pharmacokinetics of diuretics, the problem of diuretic resistance, the tactics of using thiazides and loop diuretics in patients with various stages of chronic kidney disease ...
A. I. Dyadyk, G. G. Taradin, Yu. V. Suliman, S. R. Zborovskyy, V. I. Merkuriev   +4 more
doaj   +1 more source

Bumetanide: Potent New “Loop” Diuretic [PDF]

BMJ, 1972
Bumetanide, a pharmacologically new diuretic, was evaluated in 27 subjects. Its onset of action was within 30 minutes with a peak at 90 minutes and a total duration of action of about 270 minutes. In a controlled study in oedematous patients it was equipotent with frusemide at one-fortieth the molar dosage and did not differ from frusemide with regard ...
M J, Asbury, P B, Gatenby, S, O'Sullivan, E, Bourke   +3 more
openaire   +2 more sources

Genomics and precision medicine for clinicians and scientists in hypertension [PDF]

, 2017
No abstract ...
Delles, Christian, Dominiczak, Anna, Padmanabhan, Sandosh   +2 more
core   +1 more source